Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review

Frontiers in Immunology

Immunology

Hehe Li¹  Jianhong Chen²  Hongfeng Lin²  Zhongyan Zhang²  Xin Wang²  Huimin Sun³ 

[1] Department of Geriatrics, Weifang People’s Hospital, Weifang, China;Department of Hepatobiliary Surgery, Weifang People’s Hospital, Weifang, China;Department of Pathology, Weifang People’s Hospital, Weifang, China;

关键词: advanced intrahepatic cholangiocarcinoma;    immunotherapy;    chemotherapy;    conversion therapy;    surgical resection;   

DOI  :  10.3389/fimmu.2023.1230261

 received in 2023-05-28, accepted in 2023-08-08,  发布年份 2023

来源: Frontiers

【 摘 要 】

Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the preferred treatment for ICC. However, most patients are only diagnosed at an advanced stage and are therefore not eligible for surgery. Herein, we present a case of advanced ICC in which radical surgery was not possible due to tumor invasion of the second porta hepatis and right hepatic artery. Six treatment cycles with a gemcitabine and oxaliplatin (GEMOX) regimen combined with camrelizumab immunotherapy achieved a partial response and successful tumor conversion, as tumor invasion of the second porta hepatis and right hepatic artery was no longer evident. The patient subsequently underwent successful radical surgical resection, including hepatectomy, caudate lobe resection, and cholecystectomy combined with lymph node dissection. Cases of patients with advanced ICC undergoing surgical resection after combined immunotherapy and chemotherapy are rare. The GEMOX regimen combined with camrelizumab demonstrated favorable antitumor efficacy and safety, suggesting that it might be a potential feasible and safe conversion therapy strategy for patients with advanced ICC.

【 授权许可】

Unknown   
Copyright © 2023 Zhang, Wang, Li, Sun, Chen and Lin